Orchestra BioMed Holdings (OBIO) Accumulated Expenses (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has 7 years of Accumulated Expenses data on file, last reported at $1.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 15.81% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 15.81% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 59.26% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.2 million, down from $4.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for OBIO reached as high as $7.0 million in Q3 2024 and fell as low as $202931.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $3.2 million across 5 years, with a median of $2.7 million in 2023.
• Across the five-year window, Accumulated Expenses surged 17425.26% in 2022 and sank 71.84% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $2.5 million in 2022, then climbed by 7.3% to $2.7 million in 2023, then slipped by 1.84% to $2.6 million in 2024, then soared by 59.26% to $4.2 million in 2025, then sank by 72.36% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.2 million in Q1 2026, $4.2 million in Q4 2025, and $6.8 million in Q3 2025.